We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Integumen Plc | LSE:SKIN | London | Ordinary Share | GB00BMGWZY29 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 28.00 | 28.00 | 29.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2019 to May 2024
TIDMSKIN
RNS Number : 2403F
Integumen PLC
11 July 2019
AIM share code: SKIN
11 July 2019
Integumen PLC
("Integumen" or "Company")
Exercise of Warrants (update)
Further to the announcement headed "Exercise of Warrants" notified on 10 July 2019, the Company confirms that application has been made for the 803,572 ordinary shares referred to in that announcement to be admitted to trading on AIM, which is expected to be on or about 16 July 2019. These shares will rank pari passu with the ordinary shares of the Company in issue.
Hot Features
Premium
Integumen plc Gerard Brandon, CEO +44 (0) 7340 055 648
SPARK Advisory Partners
Limited Neil Baldwin/Vassil
(Nominated Adviser) Kirtchev +44 (0) 113 370 8974
--------------------- ---------------------
Turner Pope Investments
(TPI) Limited (Broker) Andy Thacker +44 (0) 20 3621 4120
--------------------- ---------------------
About Integumen:
Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.
The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
IOESFWSUFFUSEDW
(END) Dow Jones Newswires
July 11, 2019 05:38 ET (09:38 GMT)
1 Year Integumen Chart |
1 Month Integumen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
